Pediatric Liver Transplantation as Enzyme Replacement Therapy for Rare Metabolic Diseases with No Structural Liver Damage

Objective: Very rare monogenic metabolic diseases without structural liver damage can be cured by liver transplantation. This process is a surgical enzyme replacement therapy, and defective enzymes may or may not be confined to the liver. The aims of this single center study of children with metabolic diseases showing structurally normal liver parenchyma were to analyze the indications and post-operative outcomes of liver transplantation, identification of developmental and metabolic benefits of the procedure with recognition of peri-operative difficulties to improve the success rate. Materials and Methods: Patients under the age of 19-year-old who underwent liver transplantation for metabolic disorders with no structural liver injury between January 2015 and June 2021 analyzed retrospectively. Patient and graft survivals, indications for transplantation, presence of extra-hepatic enzyme deficiency causing other organ damage, inclusion of simultaneous or sequential kidney transplantation, immunosuppressive protocols, post-transplant complications, and metabolic outcomes were identified. Results: Eight children with primary hyperoxaluria type 1 (n = 4), Maple syrup urine disease (n = 1), Crigler-Najjar syndrome type 1 (n=1), familial hypercholesterolemia (n=1) and propionic acidemia (n = 1) received left lobe (n=6) and left lateral segment (2) allografts from living donors. The median age of 4 girls and 4 boys at time of transplantation was 6.8 years (range 2.2-12.7 years). The median follow-up time was 3.3 years (range 1.5-5.7 years). The most common post-transplant complications were biliary system complications and infections and, two patients died because of sepsis. Six patients are alive with normal functioning allografts and metabolically stable on unrestricted diet. Conclusion: Liver transplantation is a lifesaving treatment and improves patient’s and parent’s life quality for metabolic disorders with no parenchymal injury despite strict dietary restrictions and medical therapies. Especially, living donor liver transplantation is very important for populations with very low organ donation rates.

PDF

___

[1] Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 1: Liverbased metabolic disorders without liver lesions. Clin Res Hepatol Gastroenterol 2011; 35(3): 194-203.
[2] Mazariegos G, Shneider B, Burton B, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab 2014; 111(4): 418-27.
[3] Hansen K, Horslen S, Metabolic liver disease in children. Liver Transpl 2008; 14: 713–733.
[4] Kayler LK, Merion RM, Lee S et al, Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002; 6: 295–300.
[5] Kayler LK, Rasmussen CS, Dykstra DM et al, Liver transplantation in children with metabolic disorders in the United States. Am J Transplant 2003; 3: 334-339.
[6] Stevenson T, Millan MT, Wayman K et al. Long-term outcome following pediatric liver transplantation for metabolic disorders. Pediatr Transplant 2010; 14: 268–275.
[7] Sokal EM, Sokol R, Cormier V et al, Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 158 (Suppl. 2) 1999: 81–84.
[8] McKiernan PJ, Ganoza A, Squires JE et al. Evolving Trends in Liver Transplant for Metabolic Liver Disease in the United States. Liver Transpl 2019; 25(6): 911-921.
[9] Hadžić N. Metabolic Indications for Pediatric Liver Transplantation: A Slow Train Coming. Liver Transpl 2019; 25(6): 829-830.
[10] Kwong A, Kim WR, Lake JR et al. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant 2020; 20 Suppl s1: 193- 299.
[11] Kasahara M, Sakamoto S, Fukuda A. Pediatric living-donor liver transplantation. Semin Pediatr Surg 2017; 26(4): 224- 232.
[12] Hong SK, Yi NJ, Yoon KC et al. Outcomes of Pediatric Liver Transplantation in Korea Using Two National Registries. J Clin Med 2020; 9(11): 3435.
[13] Cochat P, Liutkus A, Fargue S, et al. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006; 21(8): 1075- 81.
[14] Fargue S, Harambat J, Gagnadoux MF et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009; 76(7): 767-73.
[15] Cibrik DM, Kaplan B, Arndorfer JA et al. Renal allograft survival in patients with oxalosis. Transplantation 2002; 74(5): 707-10.
[16] McDonald JC, Landreneau MD, Rohr MS et al. Reversal by liver transplantation of the complications of primary hyperoxaluria as well as the metabolic defect. N Engl J Med 1989; 321(16): 1100-3.
[17] Perera MT, McKiernan PJ, Sharif K et al. Renal function recovery in children undergoing combined liver kidney transplants. Transplantation 2009; 87(10): 1584-9.
[18] Kemper MJ. The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res 2005; 33(5): 376-9.
[19] Malla I, Lysy PA, Godefroid N et al. Two-step transplantation for primary hyperoxaluria: cadaveric liver followed by living donor related kidney transplantation. Pediatr Transplant 2009; 13(6): 782-4.
[20] Ozer A, Aktas H, Bulum B et al. The experience of combined and sequential liver and kidney transplantation from a single living donor in patients with primary hyperoxaluria type 1. Pediatr Transplant 2019; 23(4): e13406.
[21] Mazariegos GV, Morton DH, Sindhi R et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012; 160(1): 116-121.
[22] Celik N, Kelly B, Soltys K et al. Technique and outcome of domino liver transplantation from patients with maple syrup urine disease: Expanding the donor pool for live donor liver transplantation. Clin Transplant 2019; 33(11): e13721.
[23] Celik N, Squires JE, Soltys K et al. Domino liver transplantation for select metabolic disorders: Expanding the living donor pool. JIMD Rep 2019; 48(1): 83-89.
[24] Barshes NR, Vanatta JM, Patel AJ et al. Evaluation and management of patients with propionic acidemia undergoing liver transplantation: a comprehensive review. Pediatr Transplant 2006; 10(7): 773-81.
[25] Rela M, Battula N, Madanur M et al. Auxiliary liver transplantation for propionic acidemia: a 10-year followup. Am J Transplant 2007; 7(9): 2200-3.
[26] Fraser JL, Venditti PC. Methylmalonic and Propionic Acidemias: Clinical Management Update. Curr Opin Pediatr 2016; 28(6): 682–693.
[27] Strauss KA, Ahlfors CE, Soltys K et al. Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier. Hepatology 2020; 71(6): 1923-1939.
[28] Varret M, Abifadel M, Rabes JP et al. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Genet 2008; 73(1): 1-13.
[29] Bilheimer DW, Goldstein JL, Grundy SM et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311(26): 1658-64.
[30] Sokal EM, Ulla L, Harvengt C et al. Liver transplantation for familial hypercholesterolemia before the onset of cardiovascular complications. Transplantation 1993; 55(2): 432-3.
[31] Revell SP, Noble-Jamieson G, Johnston P et al. Liver transplantation for homozygous familial hypercholesterolaemia. Arch Dis Child 1995; 73(5): 456-8.
[32] East C, Grundy SM, Bilheimer DW. Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolemia following liver transplantation. JAMA 1986; 256(20): 2843-8.
[33] Ishigaki Y, Kawagishi N, Hasegawa Y et al. Liver Transplantation for Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb. 2019; 26(2): 121-127.